Why Biomanufacturing Scale-Up Changes the Investor Story

Biomanufacturing scale-up changes the investor story because the company now has to show that its biology can become a reliable production system. Investors start asking about repeatability, plant economics, supply, product quality, customer demand and a capital plan that fits the infrastructure. The science stays in the story, and it becomes one chapter of several.

What changes when a biotech company starts to scale?

A process that works in a two-litre vessel can behave differently in a large one. Mixing, oxygen transfer, heat removal, contamination, feedstock consistency, downstream recovery and process control all change with volume, and the effects depend on the organism and the product. Jason Crater and Jefferson Lievense describe these problems in practical terms in their paper on the scale-up of industrial microbial processes. Their account is a useful reading list for any founder about to promise a scale-up date.

The investor needs to know what scale has already been demonstrated and which technical questions remain open at the next one. It is a short question with a long answer. A deck that answers with "proven technology" invites the diligence team to find the gaps themselves. A deck that names the open questions, and the tests that will close them, gives the investor something to underwrite. If your readers need the field explained first, point them to our primer on what industrial biotechnology is.

The plant joins the thesis

Early biotech investing tends to centre on intellectual property, team, product and market. At manufacturing scale the plant itself starts to set capital intensity, margin, ramp timing and risk. Investor questions move towards facility strategy, contract manufacturing against owned assets, equipment, capacity, utilisation, commissioning, quality systems, feedstock contracts and operating cost.

The capital profile changes with it. The OECD has published work on financing instruments and policy levers to harness biomanufacturing for climate, biodiversity and growth, treating the financing of production capacity as a policy question in its own right. OECD work on biosolutions also names demonstration and scale-up as hard stages to finance, because they need manufacturing facilities, biorefineries and other infrastructure. For a founder the practical consequence is local. The investor story needs enough project reality, a site, an equipment list, a quote or two and an operating model, to make the financial model believable.

Repeatability beats a record run

A record result in a controlled run is useful evidence. Manufacturing needs repeatability. Investors will want to know the typical range of performance, what causes variation, how often a batch misses specification, how the team recovers from an upset and what quality system exists to catch problems before a customer does. Show the distribution of results across runs, and show the failed runs with what the team learned from each.

The story shifts from "look what we achieved" to "here is the operating range we can manage". That shift reads as maturity. It also protects the company later, because a plant that performs inside a range it promised is a success, while a plant that falls short of a best run it implied is a problem, even when both produce the same output.

Supply chains and customers enter the story

Biomanufacturing depends on inputs. Feedstock, nutrients, consumables, equipment, specialist labour and downstream partners can all become constraints at scale. If the company claims supply resilience for its customers, its own supply chain needs evidence too. A biological route can remove one dependency and add another, and investors know it.

Scale-up is also incomplete when the fermenter runs. The output has to work for customers at the required quality and consistency. Customer qualification, regulatory status, specification and application testing become central evidence, and they often take longer than the engineering. This is the point where a technology platform becomes a product business, a transition covered in more depth in from fermentation platform to commercial product.

Solar Foods and Factory 01

Solar Foods makes Solein, a protein ingredient grown using air as a raw material. Its public announcements show the point every biomanufacturing founder reaches, when the evidence moves from the organism to a plant. The company launched Factory 01 and described it as the world's first factory growing food out of thin air. It later announced that Factory 01 had reached its productivity targets.

The order of that public record is instructive for any founder planning a raise. The first announcement named a plant. The second reported a production milestone at that plant against targets the company had set. Each is the kind of statement an investor can check and build a model on. The science behind Solein is still part of the company's story, and the investor-relevant evidence now sits at the level of a factory and its performance.

Show the scale gates

Investors find it easier to fund risk reduction they can see. Define the gates your next rounds will pass through and say which evidence closes each one. The gates vary by company, and a typical sequence looks like this.

1. Technical performance at the current scale.
2. Repeatability and product quality across runs.
3. Customer qualification in a named application.
4. Demonstration economics against a costed model.
5. Commercial plant readiness, including site, engineering and feedstock.
6. Repeat deployment, where plant two costs less than plant one.

Timing matters as much as sequence. A scale-up story is stronger when market timing and production timing meet. If regulation, supply shortages or buyer demand are opening a window, the company needs to show it can build capacity before the window closes. If the plant takes three years, investors will want demand evidence that justifies committing now. Urgency without delivery capability reads as hype. The first commercial plant brings its own set of risks, covered in FOAK thinking for biomanufacturing.

What should the next raise buy?

Explain what the next round creates. It might be a demonstration line, a customer-qualified product, detailed engineering, first commercial capacity or a manufacturing partnership. Describe the evidence state after the money is spent, what investors will know then that they do not know today, and tie each tranche to a gate. A round that buys time without buying evidence leaves the next round facing the same questions at a higher valuation. A round that closes a named gate gives the next investor a smaller and better-defined risk to price. Policy is moving the same way. The European Commission's 2026 bioeconomy measures connect new manufacturing capacity with demand commitments and offtake, which shows where the bottlenecks sit.

Start by drafting a one-page scale plan with the gates, the evidence for each, the capital each requires and the date you expect to pass it. Use it as the spine of the deck and the data room. If the plan exposes gaps in the story, our pitch and investor narrative work starts from that page, and related articles sit in the food tech, biotech and biomanufacturing library.

Sources and further reading

• Scale-up of industrial microbial processes, Crater and Lievense, FEMS Microbiology Letters, 2018
• Financing instruments and policy levers to harness biomanufacturing for climate, biodiversity and growth, OECD
• Solar Foods Factory 01 has reached its productivity targets, Solar Foods
• Commission steps up action on EU bioeconomy, European Commission, 2026